Microcap Stock From Pharma Sector Approves Stock Split, Gave 110.5% Return In 5 Yrs, Details Inside

Vivanza Biosciences Ltd, a microcap Pharmaceuticals sector stock having a market valuation of Rs 60.08 crore has approved Stock Split. The stock in its regulatory filing on 24 January 2023 has informed investors about the stock split. Below are the key takeaways about the stock:

Vivanza Biosciences Stock Performance

The stock last traded at Rs 150.40 apiece on BSE, fallen 4.72% from its previous close. It recorded its 52-week low on 22 June 2022 at Rs 115.55 apiece and on 14 December 2022 the stock recorded its 52-week high at Rs 195 apiece. The has gained 3.16% in a week, however, in 1 month it declined 8.18%. It has given 110.5% positive return in the past 5 years.

Vivanza Biosciences Approves Stock Split

According to the Vivanza Biosciences Ltd filing to the BSE on January 23, 2023, "The Board considered the proposal for sub-division of 1 (One) equity share of the Company having face value of Rs. 10/- each into 10 (Ten) equity shares having face value of Rs. 1/- each, subject to regulatory/statutory approvals as may be required and the approval of the members of the Company. Further, the Board recommended consequential amendments in the Capital Clause of the Memorandum of Association of the Company, subject to approval of the members of the Company. The record date for the sub-division of equity shares shall be decided by the Board and will be intimated to the exchanges."

Disclaimer

The above-mentioned information is purely informational. Greynium Information Technologies and the Author are not liable for any losses caused as a result of decisions based on the article. Goodreturns.in advises users to check with certified experts before taking any investment decision.